AlloVir, Inc.

NasdaqCM:ALVR Rapport sur les actions

Capitalisation boursière : US$62.9m

AlloVir Gestion

Gestion contrôle des critères 3/4

Le PDG AlloVir est Diana Brainard, nommé en May2021, a un mandat de 3.5 ans. La rémunération annuelle totale est $ 6.06M, composée du salaire de 10.3% et des bonus 89.7%, y compris les actions et options de la société. détient directement 0.31% des actions de la société, d'une valeur de $ 193.69K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.8 ans et 4.3 ans.

Informations clés

Diana Brainard

Directeur général

US$6.1m

Rémunération totale

Pourcentage du salaire du PDG10.3%
Durée du mandat du directeur général3.5yrs
Propriété du PDG0.3%
Durée moyenne d'occupation des postes de direction5.8yrs
Durée moyenne du mandat des membres du conseil d'administration4.3yrs

Mises à jour récentes de la gestion

Recent updates

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Feb 09
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Oct 03
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Jun 23
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Mar 02
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Nov 11
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir GAAP EPS of $0.69 beats by $1.42

Aug 04

AlloVir stock surges on $126.6M securities offering

Jul 27

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Jul 27
Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21
Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02
We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06
AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01
AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07
This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08
Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.28

Nov 10

Analyse de la rémunération des PDG

Comment la rémunération de Diana Brainard a-t-elle évolué par rapport aux bénéfices de AlloVir?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$140m

Mar 31 2024n/an/a

-US$180m

Dec 31 2023US$6mUS$623k

-US$190m

Sep 30 2023n/an/a

-US$169m

Jun 30 2023n/an/a

-US$167m

Mar 31 2023n/an/a

-US$166m

Dec 31 2022US$9mUS$605k

-US$169m

Sep 30 2022n/an/a

-US$189m

Jun 30 2022n/an/a

-US$192m

Mar 31 2022n/an/a

-US$185m

Dec 31 2021US$15mUS$365k

-US$172m

Sep 30 2021n/an/a

-US$139m

Jun 30 2021n/an/a

-US$117m

Mar 31 2021n/an/a

-US$91m

Dec 31 2020US$597kn/a

-US$70m

Rémunération vs marché: La rémunération totale de Diana ($USD 6.06M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 649.63K ).

Rémunération et revenus: La rémunération de Diana a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Diana Brainard (52 yo)

3.5yrs

Titularisation

US$6,056,943

Compensation

Dr. Diana M. Brainard, MD., served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2...


Équipe de direction

NomPositionTitularisationCompensationPropriété
David Hallal
Executive Chairman of the Board6.2yrsUS$347.00k2.45%
$ 1.5m
Diana Brainard
CEO & Director3.5yrsUS$6.06m0.31%
$ 193.7k
Vikas Sinha
President5.8yrsUS$2.94m0.85%
$ 536.0k
Edward Miller
General Counsel & Secretary5.8yrsUS$1.89m0.38%
$ 236.4k
Brett Hagen
Chief Accounting Officer5.8yrspas de données0.012%
$ 7.8k
Ann Leen
Chief Scientific Officer11.8yrspas de donnéespas de données
Cintia Piccina
Chief Commercial Officer1.4yrspas de donnéespas de données

5.8yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de ALVR est chevronnée et expérimentée (5.8 années d'ancienneté moyenne).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
David Hallal
Executive Chairman of the Board6.2yrsUS$347.00k2.45%
$ 1.5m
Diana Brainard
CEO & Director4.3yrsUS$6.06m0.31%
$ 193.7k
Vikas Sinha
President5.8yrsUS$2.94m0.85%
$ 536.0k
John Mellors
Member of the Scientific Advisory Board1.8yrspas de donnéespas de données
Malcolm Brenner
Independent Non-Executive Director12.8yrsUS$196.28k0.20%
$ 126.0k
Jeffrey Bornstein
Independent Non-Executive Director4.3yrsUS$211.78k0.066%
$ 41.4k
Michael Boeckh
Member of Scientific Advisory Board1.8yrspas de donnéespas de données
John DiPersio
Member of Scientific Advisory Board1.8yrspas de donnéespas de données
Anil Chandraker
Member of Scientific Advisory Board1.8yrspas de donnéespas de données
Morana Jovan-Embiricos
Independent Non-Executive Director5.5yrsUS$209.28k8.66%
$ 5.4m
Shawn Tomasello
Independent Director2.7yrsUS$200.73k0.031%
$ 19.3k
Juan Vera
Non-Executive Director10.8yrsUS$187.00k2.08%
$ 1.3m

4.3yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ALVR sont considérés comme expérimentés (ancienneté moyenne 4.3 ans).